By Josh White
Date: Monday 27 Oct 2025
(Sharecast News) - Bioventix reported lower annual profits on Monday, as weakness in its core markets, particularly China, offset gains from growing demand for its neurological diagnostic antibodies.
By Josh White
Date: Monday 31 Mar 2025
(Sharecast News) - Bioventix reported a marginal rise in revenue for the six months ended 31 December on Monday, with profit before tax dipping slightly due to higher research and development expenditure.
By Iain Gilbert
Date: Thursday 31 Oct 2024
(Sharecast News) - Bioventix revealed on Thursday that chief financial officer Bruce Hiscock had acquired 333 ordinary shares in the London-listed antibodies development and supply company.
| Currency | UK Pounds |
| Share Price | 2,075.00p |
| Change Today | -25.00p |
| % Change | -1.19 % |
| 52 Week High | 3,775.00p |
| 52 Week Low | 1,835.00p |
| Volume | 2,113 |
| Shares Issued | 5.22m |
| Market Cap | £108.42m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| 2nd Interim | 1st Interim | |
| Ex-Div | 06-Nov-25 | 10-Apr-25 |
| Paid | 21-Nov-25 | 25-Apr-25 |
| Amount | 80.00p | 70.00p |
| Time | Volume / Share Price |
| 16:04 | 38 @ 2,091.00p |
| 15:50 | 47 @ 2,091.00p |
| 15:49 | 181 @ 2,050.00p |
| 15:24 | 256 @ 2,092.00p |
| 14:33 | 181 @ 2,075.00p |
| CEO | Peter John Harrison |
| Chair | Ian James Nicholson |
| CFO | Bruce Hiscock |
You are here: research